Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

Table 2 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort (progression-free survival), n (%)

Dependent: Survival (PFS/30, status PFS)		All	HR (univariable)	HR (multivariable)
Gender	Male	80 (63.0)
	Female	47 (37.0)	1.11 (0.74-1.66, P = 0.619)
Age	≤ 60	51 (40.2)
	> 60	76 (59.8)	0.87 (0.58-1.31, P = 0.514)
ECOG	0-1	110 (86.6)
	2	17 (13.4)	0.54 (0.28-1.01, P = 0.055)	0.56 (0.30-1.07, P = 0.079)
Number of metastatic organs	1	28 (22.0)
	≥ 2	99 (78.0)	2.22 (1.34-3.68, P = 0.002)	2.14 (1.28-3.57, P = 0.004)
Primary tumor location	Right colon	31 (24.4)
	Left colon and rectum	96 (75.6)	0.94 (0.59-1.49, P = 0.800)
Liver metastasis	No	48 (37.8)
	Yes	79 (62.2)	1.39 (0.91-2.11, P = 0.126)
Lung metastasis	No	47 (37.0)
	Yes	80 (63.0)	1.01 (0.67-1.52, P = 0.966)
RAS	Wild-type	34 (26.8)
	Mutation	69 (54.3)	1.02 (0.65-1.59, P = 0.932)
	Unknown	24 (18.9)	0.63 (0.33-1.20, P = 0.159)
Treatment regimen	Targeted drug + PD-1	88 (69.3)
	TAS102 + bevacizumab	39 (30.7)	1.43 (0.94-2.18, P = 0.094)	1.23 (0.80-1.88, P = 0.348)

n = 127, events = 100, likelihood ratio test = 16 on 3 (P = 0.001). HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group; PD-1: Programmed cell death 1; PFS: Progression-free survival; TAS-102: Trifluridine/tipiracil.